April 11, 2025 a 08:31 pm
ELV: Analysts Ratings - Elevance Health Inc.
Elevance Health Inc., with its comprehensive portfolio of medical, digital, pharmacy, and care solutions, continues to attract attention from analysts. Given its scale and recent branding evolution, the stock has shown resilience. Current analyst ratings suggest a stable outlook with room for growth, reflecting the company's expansive reach and adaptability in the healthcare sector.
Historical Stock Grades
The recent data for Elevance Health Inc. shows a predominantly positive sentiment among analysts. As of April 2025, the ratings are as follows:
| Rating | Count | Score |
|---|---|---|
| Strong Buy | 5 | |
| Buy | 14 | |
| Hold | 4 | |
| Sell | 0 | |
| Strong Sell | 0 |
Sentiment Development
The sentiment towards Elevance Health Inc. has remained steady over recent months. The analysis reveals the following trends and shifts:
- The number of analysts maintaining a "Strong Buy" rating has shown a slight decrease from previous months.
- "Buy" ratings have consistently been the dominant recommendation, highlighting a strong confidence in the stock's potential.
- "Hold" ratings have seen minor fluctuations, indicating some analysts are opting for caution.
Overall, the total number of ratings has been relatively stable, with no significant short-term volatility.
Percentage Trends
Analyzing the percentage distribution of ratings provides further insights:
- There is a significant shift towards "Buy" recommendations, comprising over 60% of total ratings.
- "Strong Buy" ratings have decreased, which might indicate a tempered enthusiasm or tactical reassessment.
- The absence of "Sell" and "Strong Sell" ratings underscores a general positive sentiment towards the stock.
In summary, the past six months have shown a notable consolidation of "Buy" recommendations, with a decrease in aggressive "Strong Buy" stances.
Latest Analyst Recommendations
The following table presents the most recent analyst recommendations for Elevance Health Inc.:
| Date | New Recommendation | Last Recommendation | Publisher |
|---|---|---|---|
| 2025-04-09 | Outperform | Outperform | Mizuho |
| 2025-01-29 | Hold | Hold | Argus Research |
| 2025-01-28 | Overweight | Overweight | Wells Fargo |
| 2025-01-24 | Overweight | Overweight | Cantor Fitzgerald |
| 2025-01-24 | Overweight | Overweight | Barclays |
Analyst Recommendations with Change of Opinion
Recent changes in analyst opinions are documented below, indicating notable re-evaluations:
| Date | New Recommendation | Last Recommendation | Publisher |
|---|---|---|---|
| 2024-10-18 | Hold | Buy | Argus Research |
| 2024-07-18 | Neutral | Buy | B of A Securities |
| 2023-07-12 | Peer Perform | Outperform | Wolfe Research |
| 2023-07-11 | Peer Perform | Outperform | Wolfe Research |
| 2023-04-27 | Overweight | Equal Weight | Morgan Stanley |
Interpretation
The market perception of Elevance Health Inc. remains largely positive, with a consistent presence of "Buy" and "Overweight" recommendations. However, the gradual reduction in "Strong Buy" ratings suggests a cautious approach, possibly due to market conditions or company-specific factors. Despite these changes, the absence of negative ratings underscores an underlying confidence in the company's stability. Overall, analyst sentiment reflects a blend of optimism tempered by prudence.
Conclusion
Elevance Health Inc. presents a balanced investment case with robust business fundamentals and widespread positive analyst sentiment. The shift from aggressive buy stances to more measured recommendations indicates a maturing view of the stock's potential. Investors might see opportunities in its broad healthcare offerings, but should remain conscious of cautious signals suggested by some downgrades. The overall trajectory suggests resilience, with analysts maintaining a favorable stance despite slight strategic re-evaluations.